Focus on Diabetes Care

Back to articles

New analysis highlights the cardiorenal benefits of SGLT2 inhibitors

KEY POINT

Use of select sodium–glucose cotransporter-2 inhibitors (SGLT2i) resulted in significant reductions in the risk of major cardiovascular (CV) events in patients with diabetes and established CV disease but not in those with only CV risk factors. However, use of these agents resulted in significant reductions in hospitalizations for heart failure and progression of renal disease in patients with or without existing atherosclerotic disease, according to results of a systematic review and meta-analysis published in the Lancet.